Psoriasis is a chronic skin disease caused by non-malignant proliferation of epidermal cells. Existing systemic drugs only treat the disease symptoms causing side effects. Hence biologics are under development. The article also presents Galen Holdings’ growth strategy and the conditions surrounding its deals regarding two psoriasis franchises in US. Since the cost of biologic drugs is likely to prohibit its use, it remains to be seen whether biologics will change the psoriasis market and Galen’s future.